UBS Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Deal Supports Thesis; Stock Move Justified
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Goldman Sachs Downgrades Medicis (MRX) to Neutral; Limited Upside From Deal Now
September 5, 2012 8:37 AM EDTGoldman Sachs downgraded Medicis (NYSE: MRX) from Buy to Neutral with a price target of $44.00 (from $42.00).
Analyst, Gregory Waterman, said, "We now see limited upside to our updated price target of $44. MRX shares rallied 38% following the announcement that the company had... More
Canaccord Genuity Maintains a 'Hold' on Medicis (MRX); Key Question Around Acquisition Is...
September 4, 2012 9:21 AM EDTCanaccord Genuity maintains a 'Hold' on Medicis (NYSE: MRX) price target of $35.00.
Analyst, Randall Stanicky, said, "It was announced that MRX will be acquired by Valeant Pharmaceuticals (NYSE: VRX) for $44 per share in cash (~ $2.6 billion), a... More
Cantor Fitzgerald Maintains a 'Hold' on Medicis (MRX); Acquisition Rewarding Patient Investors
September 4, 2012 9:02 AM EDTCantor Fitzgerald maintains a 'Hold' on Medicis (NYSE: MRX) price target of $44.00 (from $36).
Analyst, Irina Rivkind, said, " Medicis has been struggling over the past year with the underwhelming performance of its acne franchise and stagnation in recently acquired Zyclara. Other business development... More
Valeant (VRX) to Acquire Medicis (MRX) to $44/Share; Deal Valued at $2.6B
September 4, 2012 6:29 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX: VRX) and Medicis Pharmaceutical Corporation (NYSE: MRX) entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Medicis for $44.00 per share in cash.
The transaction, which values Medicis' common stock at approximately $2.6 billion, was unanimously approved by the Boards of Directors of both... More
